Press Releases

WESTLAKE, Texas, Aug. 17, 2017 — HeartSciences today announced the European launch of MyoVista® high sensitivity electrocardiograph (hsECG™) Testing Device, developed in response to the global unmet need for effective, low-cost, front-line screening of cardiac disease in both symptomatic and asymptomatic patients.

Seattle, Wash. – August 15, 2017 – Today, angelMD and the American College of Cardiology (ACC) announced a new partnership to promote engagement of cardiovascular clinicians in health care innovation and entrepreneurship. The agreement seeks to increase the exchange of knowledge in cultivating, advising, evaluating and investing in the most relevant technology solutions within cardiovascular health.

Vascular Dynamics, Inc., (VDI) a privately held medical device company developing novel solutions for the treatment of hypertension, today announces that the United States Food and Drug Administration (FDA) has approved the company’s Investigational Device Exemption (IDE) application to initiate its pivotal trial for its MobiusHD® System for the treatment of resistant hypertension.

ST. LOUIS, Aug. 10, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the second quarter ended June 30, 2017.

Minneapolis Heart Institute Foundation® announced it has enrolled the first-in-the-world patient in a clinical study to evaluate a minimally invasive clip-based repair system made by Abbott (a company based near Chicago), for treating people with moderate or severe tricuspid regurgitation (TR), a common condition affecting the right side of the heart.

DUBLIN - July 30, 2017 - Medtronic plc (NYSE: MDT) today announced that it has completed the previously announced sale of its Patient Care, Deep Vein Thrombosis (Compression), and Nutritional Insufficiency businesses within the Patient Monitoring & Recovery (PMR) division of its Minimally Invasive Therapies Group (MITG) to Cardinal Health Inc. (NYSE: CAH) for $6.1 billion in cash.

InTouch Health, the leading enterprise telehealth platform, announced today a partnership agreement with Cardiovascular Institute of the South (CIS) to provide remote medical services geared towards emergent and general cardiology expertise in acute settings, adding a fourth service line to the company's physician capacity management offering. CIS will increase breadth and depth of adoption of InTouch Health's services, and extend its cardiology expertise to InTouch Health in two critical ways: (1) addition of cardiologists to InTouch Health's physician capacity management offering, and (2) collaboration on development of workflow solutions to drive best practices and allow for standardized quality of care in telecardiology settings.

ST. LOUIS, July 25, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS) and Princess Grace Hospital in Monaco today announced the publication of a study comparing the speed of lesion formation of magnetic catheters using the Niobe® system to manually controlled contact force catheters.

NEW YORK - July 21, 2017 -The Cardiovascular Research Foundation (CRF) is pleased to announce that the first issue of Structural Heart: The Journal of the Heart Team is now available online.

SAN FRANCISCO, July 19, 2017 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, announced today the appointment of Bruce G. Bodaken, member of the faculty at University of California, Berkeley in the Division of Health Policy Management, and Ralph Snyderman, M.D., Chancellor Emeritus and James B. Duke Professor of Medicine at Duke University to its Board of Directors.

Ra Medical Systems, makers of excimer lasers and catheters for cardiovascular and dermatological diseases, today announced that the United States Patent and Trademark Office (USPTO) has granted the Company a broad patent (No. 9700655) that covers Ra Medical Systems’ DABRATM catheter for cardiovascular disease treatment.

TEL AVIV, ISRAEL — A review appearing in the July 18 issue of the Journal of the American College of Cardiology (JACC) discusses current and next-generation implantable hemodynamic monitors and how new approaches focused on the direct measurement of left atrial pressure (LAP), seek to expand the use of pressure-guided congestive heart failure (CHF) management.

CARLSBAD, Calif. – July 11, 2017 – Following the €1.9 billion ($2.16 billion) purchase of The Spectranetics Corporation (NASDAQ:SPNC) by Royal Philips (NYSE:PHG), Ra Medical Systems, makers of cardiovascular and dermatology catheters and excimer lasers, today announced the appointment of two new members to the Company’s Board of Directors.

Minneapolis, MN, July 11, 2017 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary platform designed to address an unmet technology need within the $4+ billion electrophysiology (EP) marketplace, today announced that the Company has engaged Health Research International (HRI) to compile essential market data and help perform strategic planning for its PURE EP(TM) platform technology.

TUCSON, Ariz., July 10, 2017 /PRNewswire/ -- COPD hospitalizations are at an all-time high. The 30-day readmission rate for patients ranges from 20-39 percent1-3, with related healthcare costs at an estimated $50 billion. A recently published study, funded by Royal Philips (NYSE: PHG, AEX: PHIA), revealed that although positive airway pressure (PAP) therapy was associated with a reduction in hospitalization, more than 92 percent of patients studied were not receiving it in any form.

TUSTIN, Calif., July 7, 2017 – Cardiac patients at Lancaster General Hospital in Lancaster, Pa., can enjoy state-of-the-art CT technology for faster and safer exams with the facility’s AquilionTM ONE ViSION Edition system from Toshiba Medical, a Canon Group company. With the premium system, physicians at Lancaster General Health/Penn Medicine are able to efficiently image a wide variety of patients and are investigating the implementation of CT myocardial perfusion to improve cardiac patient care.

Medtronic Japan Co., Ltd. (head office, Minato-ku, Tokyo; president, Tony Semedo) will release a drug-eluting stent Resolute OnyxTM Coronary Stent System (hereafter, Resolute Onyx; Medical Device Approval No. 22900BZX00186000; product name, Resolute OnyxTM Coronary Stent System) on July 10th.

WASHINGTON--(BUSINESS WIRE)--GE Healthcare and HeartFlow, Inc. announced today at SCCT2017, the annual scientific meeting of the Society of Cardiovascular Computed Tomography, that they have entered into a global collaboration agreement with the goal of increasing the clinical availability and adoption of HeartFlow FFRct, a proprietary technology that helps clinicians diagnose and treat patients with suspected coronary artery disease (CAD).

IRVINE, Calif., July 5, 2017 – Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced it received U.S. Food and Drug Administration (FDA) approval for its INSPIRIS RESILIA aortic valve, the first in a new class of resilient heart valves.

RARITAN, N.J., June 28, 2017 /PRNewswire/ -- Janssen Research & Development, LLC announced today the U.S. Food and Drug Administration (FDA) accepted for Priority Review a supplemental New Drug Application (sNDA) for XARELTO® (rivaroxaban) to include a 10 mg once-daily dose for reducing the risk of VTE after at least six months of standard anticoagulant therapy. This application is based on data from EINSTEIN CHOICE, which is the only study to find a non-vitamin K antagonist oral anticoagulant (NOAC), specifically two doses of XARELTO® (10 mg and 20 mg), to be superior to aspirin in reducing the risk of recurrent VTE, with comparable rates of major bleeding.

WHIPPANY, N.J., June 29, 2017 /PRNewswire/ -- Bayer has enrolled the first patient in a global Phase IV study assessing the clinical effects of riociguat in patients with pulmonary arterial hypertension (PAH), who were being treated with a Phosphodiesterase-5 inhibitors(PDE-5 inhibitors), either as monotherapy or in combination with an endothelin receptor antagonist (ERA), and who did not reach their therapeutic goal. The study, which is a part of the collaboration between Bayer and Merck, is seeking to enroll patients at 26 sites in the U.S. with a total of 100 study sites worldwide.